Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAC Regimen in Relapsed/Refractory Multiple Myeloma
NCT00085345Phase 2Withdrawn
- Sponsor
- ONCOtherapeutics
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in multiple myeloma (MM), sponsored by ONCOtherapeutics. Status: withdrawn.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00085345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085345.